Date: 2015-06-02
Type of information: Nomination
Compound:
Company: Aduro Biotech (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 2, 2015, Aduro Biotech announced that Liana Wu has joined the company as vice president, commercial. Ms. Wu, a commercial leader with over 17 years of experience in marketing, sales, and market research in biotechnology and pharmaceutical companies, has a proven record in strategy development, new product planning, market analysis and successful product launches. Prior to joining Aduro, Ms. Wu spent nine years at Onyx Pharmaceuticals (now Amgen) where she was most recently vice president, Oncology Franchise. While at Onyx, she was instrumental in overseeing the collaboration with Bayer for Nexavar and Stivarga in the U.S. Additionally, she supported the Kyprolis launch in the U.S. and commercial expansion in ex-U.S. regions. Prior to Onyx, Ms. Wu held several sales and marketing positions at Genentech, with responsibilities associated with the company\'s key oncology brands, Rituxan, Herceptin, and Tarceva. Ms. Wu holds a Master\'s in Public Health from The Johns Hopkins University and a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania.
Financial terms:
Latest news:
